Pretreatment of hydroethanolic extract of Dillenia indica L. attenuates oleic acid induced NAFLD in HepG2 cells via modulating SIRT-1/p-LKB-1/AMPK, HMGCR & PPAR-α signaling pathways

J Ethnopharmacol. 2022 Jun 28:292:115237. doi: 10.1016/j.jep.2022.115237. Epub 2022 Mar 26.

Abstract

Ethnopharmacological relevance: Dillenia indica L. is an edible plant from the Dilleniaceae family present in the forest of India and other Asian countries. Different parts of this plant are being used in the traditional system of medicines for various diseases like diabetes, indigestion, asthma, jaundice, and rheumatic pain by various rural communities. This plant is very common among Khamptis traditional healers, the rural community of the Dhemaji district of Assam, ethnic communities of Dibru-Saikhowa Biosphere Reserve of Northeast, India for various medicinal uses. It is observed as a 'vat' suppressant and 'pitta' boosting medicine in Ayurveda.

Aim of the study: The aim of this research was to evaluate the effect of hydroethanolic extract of Dillenia indica leaf (DI-HET) against non-alcoholic fatty liver disease (NAFLD) as it is reported effective against jaundice in traditional medicine. We are also planning to see the various molecular mechanisms responsible for its effect if it is efficacious.

Study design/method: An in vitro model for NAFLD was employed in this study. For this HepG2 cells were incubated with 100 μM of oleic acid (OA) for 24 h. For evaluation of the effect of DI-HET, the extracts (5 or 10 μg/mL) were pretreated to the OA group. Fenofibrate was the positive control. Various parameters relevant to lipogenesis and β-oxidation of fatty acids like intracellular lipid accumulation, reactive oxygen species (ROS), mitochondrial stress, and key proteins were studied.

Results: DI-HET significantly reduced the intracellular lipid accumulation in OA treated cells. And also substantially decreased the expression of lipogenic proteins and increased β-oxidation in the OA group. OA induced ROS generation was found to reduce with DI-HET treatment. Western blot analysis showed that the expression of LXR-α, SREBP-1C, SREBP-2, HMGCR, FAS, CD-36, and ACOX-1 were downregulated while that of SIRT-1, p-LKB-, p-AMPK, p-ACC, CPT-1, and PPAR-α upregulated in DI-HET treatment. LCMS/MS analysis showed the presence of polyphenols like naringenin, catechin, epicatechin, shikimic acid, syringic acid, vanillic acid, and kaempferol.

Conclusion: These results suggest that DI-HET is effective against NAFLD by activation of the SIRT-1/p-LKB-1/AMPK signaling pathway via polyphenols present in the extract.

Keywords: AMPK; Dillenia indica L.; HepG2 cells; NAFLD; PPAR-α.

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Dilleniaceae* / metabolism
  • Hep G2 Cells
  • Humans
  • Hydroxymethylglutaryl CoA Reductases / metabolism
  • Hydroxymethylglutaryl CoA Reductases / pharmacology
  • Hydroxymethylglutaryl CoA Reductases / therapeutic use
  • Lipid Metabolism
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • Oleic Acid / pharmacology
  • PPAR alpha / metabolism
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • Polyphenols / pharmacology
  • Reactive Oxygen Species
  • Signal Transduction
  • Sirtuins* / metabolism

Substances

  • PPAR alpha
  • Plant Extracts
  • Polyphenols
  • Reactive Oxygen Species
  • Oleic Acid
  • HMGCR protein, human
  • Hydroxymethylglutaryl CoA Reductases
  • AMP-Activated Protein Kinases
  • Sirtuins